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Background. Transplant recipients are an immunologically vulnerable patient group and are at elevated risk of Clostridioides 
difficile infection (CDI) compared with other hospitalized populations. However, risk factors for CDI post-transplant are not fully 
understood.
Methods. Adults undergoing solid organ (SOT) and hematopoietic stem cell transplant (HSCT) from January 2010 to February 
2017 at Rigshospitalet, University of Copenhagen, Denmark, were retrospectively included. Using nationwide data capture of all CDI 
cases, the incidence and risk factors of CDI were assessed.
Results. A total of 1687 patients underwent SOT or HSCT (1114 and 573, respectively), with a median follow-up time (inter-
quartile range) of 1.95 (0.52–4.11) years. CDI was diagnosed in 15% (164) and 20% (114) of the SOT and HSCT recipients, respec-
tively. CDI rates were highest in the 30 days post-transplant for both SOT and HSCT (adjusted incidence rate ratio [aIRR], 6.64; 
95% confidence interval [CI], 4.37–10.10; and aIRR, 2.85; 95% CI, 1.83–4.43, respectively, compared with 31–180 days). For SOT 
recipients, pretransplant CDI and liver and lung transplant were associated with a higher risk of CDI in the first 30 days post-trans-
plant, whereas age and liver transplant were risk factors in the later period. Among HSCT recipients, myeloablative conditioning 
and a higher Charlson Comorbidity Index were associated with a higher risk of CDI in the early period but not in the late period.
Conclusions. Using nationwide data, we show a high incidence of CDI among transplant recipients. Importantly, we also find 
that risk factors can vary relative to time post-transplant.
Keywords.  CDI; Clostridioides difficile infection; hematopoietic stem cell transplantation; solid organ transplantation.
Clostridioides difficile infection (CDI) is a leading cause of health 
care–associated diarrhea [1, 2]. Compared with other hospital-
ized patients, both solid organ (SOT) and hematopoietic stem 
cell transplant (HSCT) recipients have a 5-fold higher risk of 
CDI [3, 4], with up to 10%–33% developing CDI post-trans-
plant [5–9]. Subsequently, those experiencing post-transplant 
CDI are at an increased risk of adverse events such as mortality, 
graft failure, and graft-vs-host disease [9–13].
Currently, it is not clear why transplantation induces such 
high CDI rates. Previous studies have found that most cases of 
CDI occur within the first month post-transplant [9, 12, 14–17]. 
However, risk factors established in other populations, such as 
antibiotic use, length of hospital stay, advanced age, and the 
use of proton pump inhibitors [18], have not been consistently 
identified in SOT or HSCT studies. As transplant recipients 
represent one of the most immunologically vulnerable patient 
populations, traditional risk factors may not apply to this group. 
Alternatively, these risk factors may be so prevalent in SOT and 
HSCT recipients that they cannot serve as independent predic-
tors for CDI.
Most studies in SOT/HSCT populations trying to identify 
risk factors for CDI have used patient records from the trans-
plant hospital, without access to patient information or fol-
low-up after discharge. This could lead to an underestimation of 
CDI post-transplant, due to patients contracting CDI outside of 
their transplant hospital. Additionally, important pretransplant 
risk factors, such as previous CDI episodes or antibiotic use at 
nontransplant hospitals, may not have been captured.
Therefore, we aimed to determine the incidence of CDI in 
a large retrospective cohort of both SOT and HSCT recipients 
in Denmark and to investigate/identify associated risk factors. 
Our setting allows complete follow-up and national capture of 
both inpatient and outpatient CDI cases [19].
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METHODS
Patient Population and Study Design
This was a cohort study of adults (aged ≥18  years), resident 
in Denmark, undergoing SOT or HSCT between January 1, 
2010, and February 21, 2017, at Rigshospitalet, University 
of Copenhagen, Denmark. The study was approved by the 
Danish Data Protection Agency (2012-58-0004; RH-2016–
47; 04433)  and the Danish National Board of Health 
(3-3013-1060/1/).
Data Sources
Data were retrieved from the Centre of Excellence for 
Personalised Medicine for Infectious Complications in Immune 
Deficiency (PERSIMUNE) [20] data warehouse, which con-
tains demographic, clinical, and para-clinical data from elec-
tronic health records through regional and national electronic 
data repositories in Denmark. Microbiology data were retrieved 
from the Danish Microbiology Database (MiBa) and used for 
national surveillance of both hospital-acquired and communi-
ty-acquired CDI [19]. Medication data were manually collected 
first from electronic medication systems and then crossed-ref-
erenced with electronic patient charts by 2 independent review-
ers. For additional information regarding data sources, please 
see the Supplementary Data.
Clostridioides difficile Testing
Due to the national nature of the microbiology data, testing for 
C. difficile could, in principle, have been performed at any of the 
microbiology departments in Denmark. Testing for C. difficile 
was not performed routinely and was conducted at the discre-
tion of hospital physicians or general practitioners in Denmark 
during the study period. Therefore, all testing was considered to 
be based on clinical symptoms (ie, diarrhea).
Definitions
CDI was defined as a positive toxigenic culture (ie, a culture 
with growth of C. difficile and which tested positive for C. dif-
ficile toxin genes) or a positive toxin test (ie, a positive poly-
merase chain reaction test for C. difficile toxin genes without a 
culture of C. difficile). Cultures with growth of C. difficile and a 
negative toxin test within 30 days of the original culture were 
not considered CDI cases. Cultures with a growth of C. diffi-
cile and no performed toxin test (ie, it was unknown whether 
the C. difficile bacterium found was toxigenic) were considered 
CDI cases. The first CDI episode after transplantation had to be 
>30 days from a pretransplantation CDI episode.
Statistical Analysis
The primary outcome was the first CDI episode after trans-
plantation. Patients were followed from transplantation until 
February 21, 2017, death, emigration, retransplantation, or 
post-transplant CDI, whichever came first.
Patient characteristics were compared for those with and 
without posttransplantation CDI using the Wilcoxon-Mann-
Whitney (for continuous variables) and chi-square (for 
categorical variables) tests. If there were <5 patients in a cat-
egorical group, the Fisher exact test was used instead of the 
chi-square test.
To investigate whether the rates of CDI post-transplantation 
were elevated compared with pretransplantation rates, inci-
dence rates of CDI were calculated including the 6 months be-
fore transplant. For this analysis, baseline was thus redefined 
as 180 days before the transplantation date or January 1, 2010, 
whichever occurred later. The crude incidence rate (IR) of CDI 
was calculated per 100 person-years of follow-up for each trans-
plantation type in the following time periods: pretransplanta-
tion (up to 180 days before transplantation), early (0–30 days 
post-transplantation), middle (31–180  days post-transplanta-
tion), and late (>180 days post-transplantation). Crude IRs were 
calculated with censoring after the first CDI episode (irrelative 
of time period) and compared with crude IRs when repeated 
events were allowed (excluding 30 days between events).
Poisson regression was used to investigate the following 
risk factors for post-transplant CDI: pretransplantation CDI, 
transplant type, time from transplantation, the Charlson 
Comorbidity Index (CCI) [21, 22], donor/recipient serostatus 
for cytomegalovirus, and baseline levels of albumin, neutro-
cytes, and lymphocytes. The cutoffs for baseline measurements 
were those registered up to 14  days before transplantation to 
minimize measurements not reflecting the recipients’ status at 
the time of transplant. CCI was calculated based on all inpa-
tient and outpatient diagnoses up to the date of transplantation. 
Risk factors found to be significant (P < .1) in univariable mod-
els were included in the multivariable model, with those that 
were significant (P < .1) after adjustment retained in the final 
model. Models were developed separately for SOT and HSCT 
recipients.
Sensitivity analyses were performed to assess whether cen-
soring patients 1 year after transplantation and excluding those 
with <6  months of follow-up before transplantation altered 
the results. Further, the main analyses were repeated, treating 
death, emigration, and retransplantation as competing risks. 
Due to the proportionality assumption, this was done in 2 sep-
arate time periods (early [0–30 days] and combined middle and 
late periods [>30 days] post-transplantation).
Nested Case–Control Study
To assess the possible effect of medication on CDI risk, we con-
ducted a nested case–control study, matching cases and controls 
1-to-1 based on transplantation type and time of transplanta-
tion. Cases were patients who contracted CDI within the first 
60  days post-transplantation. Controls were patients who did 
not contract CDI within the first 70  days post-transplanta-
tion and had the same or a longer follow-up time relative to 
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transplantation as their matched case. Medication data assessed 
included proton pump inhibitors (PPIs), laxatives, antibiotics, 
steroids, antimycotics, and parenteral nutrition.
Medication data were collected from 90 days preceding the 
CDI episode (including before transplant if necessary) for cases 
and the corresponding time period relative to transplantation 
for controls. The number of days on each type of medication 
was calculated as the total number of time period days (ie, when 
2 different antibiotics were given on the same day, the time 
period days = 1).
Logistic regression analysis was used to investigate the 
association between medication use and post-transplant 
CDI, with those found to be significant (P < .1) in univari-
able analyses included in the multivariable model. Again, 
models were developed separately for SOT and HSCT recipi-
ents. Time period days were compared by taking the median 
number of days for all cases and controls including those not 
receiving treatment. A  sensitivity analysis was performed 
using a cumulative number of medication days (ie, when 2 
different antibiotics were given on the same day, the medi-
cation days = 2).
For additional information on medication data collection 
(including standard immunosuppression regimes), see the 
Supplementary Data and Supplementary Figure 1. For standard 
antibacterial, antifungal, and antiviral prophylactic regimes, 
please see Supplementary Table 1.
All statistical analyses were performed using SAS Enterprise 
Guide (version 7.1) and SAS (version 9.4; SAS Institute, Cary, NC).
RESULTS
Study Population
During the study period, 1687 patients underwent SOT 
or HSCT (1114 and 573, respectively), with a median fol-
low-up time (interquartile range [IQR]) of 1.9 (0.5–4.0) years 
post-transplantation. The most common SOT was kidney 
(n  =  548); followed by liver (n  =  273), lung (n  =  202), heart 
(n = 81), and pancreas (n = 10). Among these, 10 pancreas, 6 
liver, and 1 lung transplant were combined with a simultaneous 
kidney transplantation. All HSCTs were allogeneic, with non-
myeloablative (n = 326) being the most common conditioning 
type, followed by myeloablative (n  =  247). Additional patient 
characteristics can be found in Table 1.
CDI Cases
A total of 164 (15%) SOT recipients and 114 (20%) HSCT recip-
ients developed CDI post-transplant. Of these cases, 73 (45%) 
and 63 (55%) were based on a positive toxin test, 65 (40%) and 
41 (36%) on a toxigenic culture, and 26 (16%) and 10 (9%) 
on a positive culture for C.  difficile without toxin testing for 
SOT and HSCT cases, respectively. Additional information on 
CDI cases and testing methods over time can be found in the 
Supplementary Data.
The majority of CDI cases were hospital inpatients at the time 
of diagnosis (85% [n = 142] and 71% [n = 80] of SOT and HSCT 
cases respectively). Among the outpatient cases, only 46% of 
SOT recipients were tested for C. difficile at their transplant hos-
pital (ie, Rigshospitalet), whereas 75% of HSCT outpatient cases 
were tested via the outpatient clinic at Rigshospitalet. When 
combining in- and outpatient cases of CDI, C. difficile testing 
had been ordered by the transplanting hospital (Rigshospitalet) 
in most cases; however, 27% of SOT cases and 15% of HSCT 
cases had had their C. difficile test ordered at an alternative hos-
pital or health care facility.
CDI Incidence Rates
The crude incidence rate (IR) of CDI varied considerably in 
the different time periods relative to transplantation (Figure 
1). In SOT recipients, the incidence of CDI was low in the 
6-month pretransplant period (1.5/100 PYFU; 95% confi-
dence interval [CI], 0.7–3.0), peaking dramatically in the first 
month post-transplant (78.7; 95% CI, 60.0–97.4) and falling in 
the middle period (11.6; 95% CI, 8.2–15.0) but not reaching 
pretransplant levels until the late post-transplant period (1.9; 
95% CI, 1.3–2.4). Among the HSCT group, the IR in the pre-
transplant period was higher than in SOT recipients (11.6; 95% 
CI, 7.5–15.7). However, the highest rate was again in the first 
month post-transplant (61.2; 95% CI, 37.6–84.7), decreasing to 
the lowest rate in the late post-transplant period (4.2; 95% CI, 
2.8–5.6). This trend was consistent when repeated events were 
included.
Risk Factors for Post-transplant CDI
Poisson regression analysis found that transplant type, age, CDI 
before transplantation, and time since transplantation were all 
significantly associated with increased risk of CDI post-SOT 
(Table 2; Supplementary Table 2). After adjusting for these 
factors, the first 30  days post-transplant were associated with 
a 6.64 times increased risk of CDI (95% CI, 4.37–10.10) com-
pared with the middle post-transplant period. Additionally, 
liver recipients had a higher risk of CDI compared with kidney 
recipients (adjusted IR ratio [aIRR], 3.17; 95% CI, 2.23–4.49), 
and pretransplant CDI was significantly associated with an 
increased risk of post-transplant CDI.
Factors associated with post-transplant CDI in HSCT recipi-
ents were conditioning type, year of transplant, time since trans-
plantation, and CCI (Table 2; Supplementary Table 2). As with 
SOT, the greatest risk of CDI in HSCT recipients was within 
the first month post-transplant (aIRR, 2.85; 95% CI, 1.83–4.43) 
compared with the middle post-transplant period). Further, 
myeloablative recipients were associated with a higher risk of 
post-transplant CDI than nonmyeloablative recipients (aIRR, 
1.72; 95% CI, 1.17–2.25), and a higher CCI score was also asso-
ciated with an increased risk (aIRR, 1.17; 95% CI, 1.02–1.33 per 
point higher).
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Changes in Risk Factors Based on Time From Transplantation
There was a significant interaction between time since trans-
plantation and transplant/conditioning type within the SOT 
(P = .02) and HSCT groups (P < .0001). To further assess risk 
factors relative to time after transplantation, the analysis was 
split into 2 time periods: early (≤30 days post-transplant) and 
middle/late (>30 days post-transplant) (Table 2). Among SOT 
recipients, lung recipients were found to have an increased 
risk of CDI in the early post-transplant period compared with 
kidney recipients (aIRR, 3.03; 95% CI, 1.62–5.67). Also, pre-
transplant CDI was only significant in the early time period, 
whereas age was only a significant risk factor in the middle/late 
time period. Among HSCT recipients, transplantation type and 
CCI were the only significant risk factors for CDI in the early 
post-transplant period.
Sensitivity Analyses and Death as a Competing Risk
Results of the sensitivity analyses censoring patients 1  year 
after transplantation and excluding those with <6 months fol-
low-up before transplant were consistent with the main analy-
ses. Competing risk analyses were similar to the main analyses 
for HSCT. In the SOT group, the hazard ratio for lung recipients 
Table 1. Characteristics for SOT and HSCT Recipients 
SOT HSCT
 Non-CDI CDI P Valuea Non-CDI CDI P Valuea
No. 950 164 459 114
Total person-years of follow-up 2887 132  1056 84  
Median person-years of follow-up (IQR) 2.74 (1.3–4.9) 0.10 (0.0–0.8)  1.6 (0.5–3.7) 0.3 (0.1–0.7)  
Median year of transplant (IQR) 2013 (2011–2015) 2013 (2011–2014) .38 2013 (2011–2015) 2013 (2012–2015) .51
Median age (IQR), y 50 (41–59) 52 (44–60) .11 55 (43–64) 51 (38–61) .04
Age group, No. (%)       
 <40 214 (23) 30 (18) .39 97 (21) 31 (27) .07
 40–49 250 (26) 39 (24)  89 (19) 24 (21)  
 50–59 284 (30) 53 (32)  90 (20) 28 (25)  
 ≥60 202 (21) 42 (26)  183 (40) 31 (27)  
Male gender, No. (%) 583 (61) 96 (59) .5 276 (60) 69 (61) .93
Donor-recipient CMV serostatus,b No. (%)       
 High 169 (18) 23 (14) .64 144 (31) 31 (27) .747
 Intermediate 373 (39) 66 (40)  153 (33) 40 (35)  
 Low 325 (34) 61 (37)  124 (27) 35 (30)  
 Missing 83 (9) 14 (9)  38 (8) 8 (7)  
Median Charlson Comorbidity Index (IQR) 3 (2–4) 3 (2–4) .05 2 (0–2) 2 (1–3) .29
Baselinec lymphocytes, No. (%)       
 Below normal (<1.0*109/L) 263 (28) 64 (39) .001 210 (46) 52 (46) .51
 Normal (1.0–<3.5*109/L) 598 (63) 77 (47)  226 (49) 58 (51)  
 Above normal (≥3.5*109/L) 14 (2) 2 (1)  18 (4) 4 (4)  
 Missing 75 (8) 21 (13)  5 (1) 0 (0)  
Baselinec neutrocytes, No. (%)       
 Below normal (<1.6*109/L) 12 (1) 4 (2) .10 164 (36) 33 (29) .11
 Normal (1.6–<5.9*109/L) 500 (53) 81 (50)  254 (55) 74 (65)  
 Above normal (≥5.9*109/L) 365 (38) 58 (35)  34 (7) 7 (6)  
 Missing 73 (8) 21 (13)  7 (2) 0 (0)  
Baselinec albumin,d No. (%)       
 Below normal 307 (32) 77 (47) .005 16 (4) 4 (4) .99
 Normal 375 (39) 49 (30)  200 (44) 48 (42)  
 Above normal 77 (8) 10 (6)  55 (12) 14 (12)  
 Missing 191 (20) 28 (17)  189 (41) 48 (42)  
Pretransplantation CDI, No. (%)       
 Never 919 (97) 150 (92) .004 422 (92) 102 (90) .1
 Yes (not in 6 mo before Tx) 27 (3) 9 (6)  13 (3) 1 (1)  
 Yes (in 6 mo before Tx) 4 (0.4) 5 (3)  24 (5) 11 (10)  
Abbreviations: CDI, Clostridioides difficile infection; CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplant; IQR, interquartile range; SOT, solid organ transplant.
aP values were determined using the Wilcoxon-Mann-Whitney test for continuous variables and the chi-square test for categorical variables (with missing values as a category, so that all 
patients were included). If there were <5 patients in a categorical group, the Fisher exact test was used instead of the chi-square test.
bHigh for SOT = donor (D)+/recipient (R)-; high for HSCT = D-/R+; intermediate for SOT and HSCT = D+/R+; low for SOT = D-/R+; low for HSCT = D+/R-.
cBaseline measurements were those taken up to 14 days before transplantation.
dLevels for albumin: normal: age 18–39: 36–48 g/L; age 40–69: 36–45 g/L; age 70–125: 34–45 g/L; below: levels under normal per age group; above: levels above normal per age group.
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compared with kidney in the early post-transplant period 
became nonsignificant (hazard ratio, 1.95; 95% CI, 0.93–4.08). 
However, only 3 lung recipients died within the early post-trans-
plant period.
Case–Control Study for Medication Use
A total of 216 patients were included in the case–control study 
looking at the association between exposure to medication 
groups and risk of CDI (SOT n = 132, HSCT n = 84). The num-
ber of patients prescribed each medication and the median 
number of treatment days among those who were prescribed 
the medication are shown in Table 3. There was no significant 
association between the total number of time period days with 
antibiotics, antimycotics, steroid treatment, or parenteral nutri-
tion and CDI in either the SOT group or HSCT group.
Among the SOT group, only the number of different an-
tibiotic groups prescribed was significantly associated with 
increased odds of CDI among cases compared with controls in 
the multivariate model after adjusting for age, sex, transplant 
type, year of transplant, and CCI with an adjusted odds ratio 
(aOR) of 1.66 (95% CI, 1.07–2.57) per extra medication group. 
In the univariable analysis, the total number of time period days 
with carbapenems was associated with higher odds of CDI (OR, 
1.09; 95% CI, 1.02–1.18); however, this did not remain signifi-
cant in the multivariable model (aOR, 1.04; 95% CI, 0.98–1.09). 
The difference in use of carbapenems between cases and con-
trols was most prominent in liver recipients (Supplementary 
Table 3). Among the HSCT group, only treatment days with 
other antibiotics was associated with significantly higher odds 
of CDI in the multivariable model after adjusting for sex, age, 
conditioning type and year of transplant, and CCI (aOR, 1.02; 
95% CI, 1.00–1.05 per extra treatment day). This difference was 
most prominent in the nonmyeloablative group (Supplementary 
Table 3). Laxative use in the week before CDI was also border-
line significant in the multivariate analysis of HSCT cases com-
pared with controls (aOR, 2.91; 95% CI, 0.94–9.00; P = .065).
Sensitivity analyses previously described for cumulative 
medication were consistent with the above results. The univar-
iate and multivariate logistic regression analyses for the nested 
case–control study can be found in Supplementary Table 4.
DISCUSSION
This study gives a comprehensive overview of the dynamics 
of CDI relative to transplantation, with national data capture 
of both inpatient and outpatient cases, as well as extensive fol-
low-up. Consistent with other studies, we found that CDI is 
a common complication of transplantation and that the first 
month post-transplant is a high-risk period for recipients [9, 
12, 14–17]. Furthermore, we identified several CDI risk factors 
that vary depending on time post-transplant.
A key aspect of our study was access to national microbiol-
ogy data. As such, we were able to observe the incidence of CDI 
both pre- and post-transplant, across different hospitals and gen-
eral practitioners irrespective of discharge from our transplant 
hospital. This nationwide data capture showed that post-trans-
plant CDI affected 15% and 20% of SOT and HSCT recipients, 
respectively. Previously reported rates of CDI have generally been 
between 2% and 10% among SOT recipients [4, 5, 10, 11, 23] and 
8% and 15% among HSCT recipients [12, 14–16, 24–29], with a 
small number of HSCT studies also reporting rates >20% [6, 30]. 
C
ru
de
 in
ci
de
nc
e 
ra
te
300
A Crude Incidence Rates per SOT Type and Time Period
Crude Incidence Rates per HSCT Type and Time Period
Kidney (n=548) Heart (n= 81) Lung (n =202) Liver (n=273)
250
200
150
100
50
Pr
e
Ea
rly
M
idd
le
La
te
Pr
e
Ea
rly
M
idd
le
La
te Pr
e
Ea
rly
M
idd
le
La
te
Pr
e
Ea
rly
M
idd
le
La
te Pr
e
Ea
rly
M
idd
le
La
te Pr
e
Ea
rly
M
idd
le
La
te
0
C
ru
de
 in
ci
de
nc
e 
ra
te
B
Nonmyeloablative (n=326) Myeloablative (n= 247)
300
250
200
150
100
50
0
Figure 1. A, Crude incidence rates per 100 person-years of follow-up and 95% 
confidence intervals for each solid organ transplant type in the following time peri-
ods relative to transplantation: Pre: time before transplantation; Early: 0–30 days 
post-transplantation; Middle: 31–180  days post-transplantation; Late: >180  days 
post-transplantation. B, Crude incidence rates per 100 person-years of follow-up 
and 95% confidence intervals for each hematopoietic stem cell transplant type in 
the following time periods relative to transplantation: Pre: time before transplan-
tation; Early: 0–30 days post-transplantation; Middle: 31–180 days post-transplan-
tation; Late: >180 days post-transplantation. Abbreviations: HSCT, hematopoietic 
stem cell transplant; SOT, solid organ transplant.
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All the HSCTs in this study were allogenic. As allogenic HSCTs 
have a higher incidence of CDI [25], this may partly explain the 
higher observed incidence. However, our data also captured 29% 
of HSCT cases and 14% of SOT cases who were outpatients at the 
time of CDI diagnosis. Additionally, 15% and 27% of our HSCT 
and SOT cases were tested at alternative hospitals or health care 
facilities and not at our transplant hospital. These additional data 
could help explain the higher rates observed in our cohort and 
may better reflect the true burden of CDI post-transplant.
When assessing risk factors for post-transplant CDI, previ-
ous SOT studies have observed a greater risk associated with 
both liver and lung transplant recipients compared with kid-
ney recipients [10, 11]. Our findings support this; however, in 
our study, lung recipients had a higher risk of CDI only when 
assessing the first 30 days post-transplant separately from the 
whole study period. Among HSCT recipients, previous studies 
have observed a higher risk of CDI in myeloablative recipients 
compared with nonmyeloablative recipients [12, 31]. This is 
again similar to our results; however, when assessing the early 
and middle/late periods separately, the increased risk found in 
myeloablative recipients was only observed in the first 30 days 
post-transplant.
These observations of variation in the risk factors of CDI are 
important findings and suggest that host changes relative to time 
since transplant may entail different responses to C. difficile expo-
sure. Host changes could include recipients being at their most 
immunologically vulnerable time point in the early post-transplant 
period. This might be due to the varying degrees of injury to their 
own immune system (obliteration in HSCT recipients or postsur-
gery effects in SOT recipients) while simultaneously starting immu-
nosuppression (as to not reject the new immune system/organ). 
Alternatively, it is possible that there is a testing bias in our cohort. 
A treating physician may be more likely to order a stool culture early 
after transplantation, when recipients can be more clinically vulner-
able. If there is a substantial proportion of C. difficile colonization, as 
found in previous HSCT studies [29], this could lead to false-posi-
tive results, as the bacteria found in a colonized patient could be an 
incidental finding and not the actual cause of diarrhea.
Medication use did not appear to greatly affect risk of CDI 
in our study. There was a trend observed in SOT recipients of 
Table 2. Risk Factors for CDI by Post-transplantation Time Period
SOTa
 All Time Periods Post-transplantb Early Time Period Middle/Late Time Period
 Multivariate IRR (95% CI) P Value Multivariate IRR (95% CI) P Value Multivariate IRR (95% CI) P Value
Transplant type
 Kidney 1.00  1.00  1.00  
 Heart 0.50 (0.18–1.36) .1713 0.39 (0.05–2.94) .3605 0.55 (0.17–1.78) .315
 Lung 1.52 (0.96–2.40) .0738 3.03 (1.62–5.67) .0005 0.86 (0.41–1.80) .6829
 Liver 3.17 (2.23–4.49) <.0001 5.82 (3.39–9.97) <.0001 1.84 (1.08–3.14) .0243
Age at transplant (per 10 y older) 1.17 (1.02–1.34) .0278 1.08 (0.90–1.28) .4134 1.34 (1.07–3.14) .0111
Pretransplant CDIc       
 No 1.00  1.00  1.00  
 Yes (≥6 mo before Tx) 2.43 (1.17–5.03) .0172 4.35* (2.23–8.47) <.0001 1.09* (0.25–4.83) .9095
 Yes (in 6 mo before Tx 5.67 (1.89–17.02) .002     
HSCT
 All Time Periods Post-transplantb Early Time Period Middle/Late Time Period
 Multivariate IRR (95% CI) P Value Multivariate IRR (95% CI) P Value Multivariate IRR (95% CI) P Value
Transplant type       
 Nonmyeloablative 1.00  1.00  1.00  
 Myeloablative 1.72 (1.17–2.25) .0057 2.88 (2.53–5.42) .0011 1.20 (0.72–1.99) .4851
Year of transplantation (grouped)       
 2010–2011 1.00  1.00  1.00  
 2012–2013 2.25 (1.30–3.89) .0036 3.58 (1.18–10.81) .0239 2.12 (1.11–4.08) .0234
 2014–2015 3.23 (1.87–5.60) <.0001 5.91 (2.06–16.95) .001 3.33 (1.68–6.59) .0006
 2016–2017 1.70 (0.77–3.75) .1887 2.62 (0.73–9.34) .1387 3.41 (1.12–10.41) .0311
CCI score       
 Per point higher 1.17 (1.02–1.33) .0224 1.20 (1.00–1.44) .0453 1.17 (0.95–1.44) .1434
Abbreviations: CCI, Charlson Comorbidity Index; CDI, Clostridioides difficile infection; CI, confidence interval; HSCT, hematopoietic stem cell transplant; OR, odds ratio; SOT, solid organ 
transplant.
aDue to no CDI cases, pancreas recipients were removed from the analyses.
bAlso adjusted for time since transplantation.
cPretransplant CDI <6 months before transplant or ≥6 months before transplant were combined when looking at early and middle/late time periods separately.
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Table 3. Nested Case–Control Study of Medication Use 90 Days Before CDI
SOTa HSCT
 Cases (n = 66) Controls (n = 66) P Value Case (n = 42) Control (n = 42) P Value
Age, median (IQR), y 50 (42–57) 54 (44–60) .16 48 (40–60) 52 (39–62) .53
Male, No. (%) 41 (62) 36 (55) .47 24 (57) 22 (52) .66
Charlson Comorbidity Index, median (IQR) 3 (2–4) 3 (1–4) .99 2 (2–3) 2 (2–3) .42
Antibioticsb       
 Received treatment, No. (%) 66 (100) 66 (100) — 42 (100) 42 (100) —
 Medianc No. of time period days (IQR) 30 (11–48) 22 (6–68) .84 59 (43–80) 52 (34–65) .09
Antibiotic groupsb,d       
 Clindamycin       
  Received treatment, No. (%) 1 (2) 0 1.00 1 (2) 4 (10) .35
  Medianc No. of time period days (IQR) 16 (–) — — 9 (–) 13 (7–23) .71
 Fluoroquinolones       
  Received treatment, No. (%) 39 (59) 33 (50) .29 37 (88) 37 (88) 1.00
  Medianc No. of time period days (IQR) 12 (6–29) 15 (6–26) .89 29 (14–44) 22 (13–38) .19
 3rd/4th-generation cephalosporins       
  Received treatment, No. (%) 27 (41) 26 (39) .85 29 (69) 18 (43) .01
  Medianc No. of time period days (IQR) 6 (4–7) 5 (5–6) .41 8 (5–11) 7.5 (4–11) .80
 Piperacillin/tazobactam       
  Received treatment, No. (%) 8 (12) 0 .006 15 (36) 16 (38) .82
  Medianc No. of time period days (IQR) 7 (5–43) — — 2 (1–5) 4 (3–14) .03
 Carbapenems       
  Received treatment, No. (%) 40 (61) 27 (41) .02 31 (74) 28 (67) .47
  Medianc No. of time period days (IQR) 13 (5–20) 11 (6–23) .75 13 (7–20) 12 (6–19) .78
 Beta-lactam/beta-lactamase inhibitor comb.  
(excl. piperacillin/tazobactam)
      
  Received treatment, No. (%) 37 (56) 33 (50) .48 30 (71) 31 (74) .80
  Medianc No. of time period days (IQR) 6 (4–7) 5 (4–6) .31 15 (7–26) 14 (7–19) .64
 Other antibiotics       
  Received treatment, No. (%) 60 (91) 58 (88) .77 42 (100) 42 (100) —
  Medianc No. of time period days (IQR) 20 (7–35) 22 (5–52) .58 31 (19–60) 22 (10–39) 0.05
No. of different antibiotic medications prescribede (IQR) 3 (2–4) 3 (2–3) .02 5 (3–5) 4.5 (3–5) .39
 1–2, No. (%) 19 (29) 26 (39)  4 (10) 3 (7)  
 3–4, No. (%) 35 (53) 37 (56)  14 (33) 18 (43)  
 >5, No. (%) 12 (18) 3 (5)  24 (57) 21 (50)  
Proton pump inhibitorsb       
 Received treatment, No. (%) 66 (100) 65 (99) 1.00 36 (86) 32 (76) .26
 Medianc No. of time period days (IQR) 49 (15–90) 28 (8–79) .03 45 (29–81) 33 (21–64) .15
Steroidsb       
 Received treatment, No. (%) 66 (100) 66 (100) — 24 (57) 17 (41) .12
 Medianc No. of time period days (IQR) 21 (12–46) 19 (9–36) .17 9 (4–26) 10 (6–21) .57
Antimycoticsb       
 Received treatment, No. (%) 48 (73) 46 (70) .70 42 (100) 41 (98) 1.00
 Medianc No. of time period days (IQR) 12 (8–31) 10 (7–21) .35 52 (36–69) 44 (30–63) .32
Parenteral nutritionb       
 Received treatment, No. (%) 1 (2) 0 1.00 23 (55) 23 (55) 1.00
 Medianc No. of time period days (IQR) 5 (–) — — 12 (8–24) 12 (6–20) .57
Received laxativesf 38 (58) 34 (52) .48 15 (36) 7 (17) .04
Abbreviations: CDI, Clostridioides difficile infection; HSCT, hematopoietic stem cell transplant; IQR, interquartile range; SOT, solid organ transplant.
aDue to no CDI cases, there were no pancreas recipients in the nested case–control study.
bWithin 90 days before CDI for cases or corresponding time period relative to transplantation for controls.
cMedian number of time period days only including those receiving the medication in question. Different types of medications within medication groups are not counted cumulatively; max 
median number of days is 90.
dAntibiotic subgroups are listed in the Supplementary Data.
eNumber of different antibiotic medications prescribed within 90 days before CDI for cases or corresponding time period relative to transplantation for controls.
fIf patients received laxatives up to 7 days before CDI for cases or corresponding time period relative to transplantation for controls.
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an increased risk of CDI with a greater number of different 
antibiotics received; however, this trend was not seen in HSCT 
recipients. Furthermore, it is worth noting the high prevalence 
medications received among all the patients in our study; for 
example, all patients received antibiotics, with the major-
ity receiving at least 3 different antibiotics during the 90-day 
observation period. Thus, we cannot rule out the possibility 
that antibiotics and other medications play a major role in the 
development of CDI among transplant recipients but that their 
prevalence is so high in this population that we could not clearly 
identify it as an independent predictor.
Limitations to our study include not knowing possible 
colonization of recipients before transplantation and not 
typing C.  difficile strains. Knowing the C.  difficile strain of 
each CDI case could indicate if patients were infecting each 
other. However, cases of CDI were not isolated incidences 
over time (Supplementary Figure 2). Furthermore, lung and 
heart recipients were treated in the same ward at our hospital 
(Rigshospitalet), and the large difference in CDI incidence be-
tween these transplant types suggests that cross-contamination 
is unlikely. An additional consideration is that pretransplant 
rates of CDI were calculated by looking back from the start 
of follow-up (time of transplantation), and, although unlikely, 
there may have been individuals with a CDI in the period who 
did not continue to have a transplant or where the transplant 
was delayed, who were thus not included in the analysis.
In conclusion, we identify a high-risk period for CDI within 
the first month after transplantation in a large cohort with na-
tional data capture of all CDI cases and extensive follow-up. This 
high-risk period appears to be particularly prominent for liver, 
lung, and myeloablative HSCT recipients. In addition, we find 
that risk factors can vary depending on time from transplanta-
tion. These are important observations, both for designing fu-
ture studies to derive risk scores for CDI in transplant recipients 
and to give a more comprehensive clinical picture of CDI in an 
immunologically vulnerable cohort.
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